Total Payments
$42,996
2024 Payments
$12,168
Companies
32
Transactions
752
Medicare Patients
3,872
Medicare Billing
$701,451
Payment Breakdown by Category
Other$25,867 (60.2%)
Food & Beverage$14,068 (32.7%)
Travel$2,018 (4.7%)
Education$1,043 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,068 | 700 | 32.7% |
| Honoraria | $13,482 | 7 | 31.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,385 | 7 | 28.8% |
| Travel and Lodging | $2,018 | 8 | 4.7% |
| Education | $1,043 | 30 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shionogi Inc | $15,797 | 71 | $0 (2024) |
| La Jolla Pharmaceutical Company | $14,766 | 43 | $0 (2024) |
| Gilead Sciences, Inc. | $2,384 | 116 | $0 (2024) |
| ViiV Healthcare Company | $1,665 | 107 | $0 (2024) |
| AstraZeneca UK Limited | $1,428 | 9 | $0 (2023) |
| Merck Sharp & Dohme LLC | $1,220 | 89 | $0 (2024) |
| Astellas Pharma US Inc | $1,122 | 53 | $0 (2024) |
| Insmed, Inc. | $977.30 | 51 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $646.76 | 40 | $0 (2024) |
| Theravance Biopharma, Inc. | $645.79 | 35 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,168 | 144 | La Jolla Pharmaceutical Company ($9,079) |
| 2023 | $16,868 | 170 | Shionogi Inc ($9,156) |
| 2022 | $9,055 | 108 | Shionogi Inc ($5,823) |
| 2021 | $988.19 | 58 | ViiV Healthcare Company ($381.06) |
| 2020 | $426.67 | 23 | ViiV Healthcare Company ($207.32) |
| 2019 | $1,020 | 79 | Merck Sharp & Dohme Corporation ($273.61) |
| 2018 | $1,142 | 86 | Theravance Biopharma, Inc. ($232.39) |
| 2017 | $1,327 | 84 | Theravance Biopharma Inc. ($413.40) |
All Payment Transactions
752 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: HIV | ||||||
| 12/19/2024 | PFIZER INC. | PANZYGA (Biological), CUTAQUIG | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 12/18/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/17/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: ANTIBIOTIC | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.69 | General |
| 12/11/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Infectious Diseases | ||||||
| 12/09/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.27 | General |
| 12/02/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: HIV | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/25/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: HIV | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.80 | General |
| 11/13/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $112.63 | General |
| Category: Infectious Diseases | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.30 | General |
| 11/12/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: HIV | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/06/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.48 | General |
| 10/29/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Kimyrsa | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: ANTIFUNGALS | ||||||
| 10/24/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ANTIBIOTIC | ||||||
| 10/23/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 10/23/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Infectious Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 947 | 58,130 | $592,862 | $162,459 |
| 2022 | 15 | 875 | 60,013 | $558,792 | $158,036 |
| 2021 | 16 | 972 | 87,718 | $664,640 | $185,876 |
| 2020 | 18 | 1,078 | 111,512 | $687,481 | $195,080 |
Total Patients
3,872
Total Services
317,373
Medicare Billing
$701,451
Procedure Codes
65
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 133 | 331 | $71,550 | $29,867 | 41.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 156 | 484 | $87,160 | $28,895 | 33.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 108 | 253 | $55,715 | $22,666 | 40.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 97 | 449 | $89,800 | $20,614 | 23.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 146 | 159 | $61,875 | $20,024 | 32.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 65 | 123 | $31,885 | $15,914 | 49.9% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 33 | 456 | $68,400 | $5,049 | 7.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $12,900 | $4,711 | 36.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 18 | 29 | $15,930 | $4,694 | 29.5% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 35 | 54,800 | $45,690 | $2,516 | 5.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $6,150 | $2,146 | 34.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 27 | 83 | $13,280 | $1,749 | 13.2% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2023 | 12 | 18 | $9,640 | $1,423 | 14.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $4,850 | $1,405 | 29.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 11 | 11 | $2,395 | $429.99 | 18.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 41 | 869 | $15,642 | $357.51 | 2.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 153 | 574 | $66,010 | $31,024 | 47.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 131 | 334 | $50,100 | $30,054 | 60.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 90 | 486 | $97,200 | $23,740 | 24.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 141 | 163 | $52,975 | $23,154 | 43.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 93 | 233 | $36,115 | $18,119 | 50.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 51 | 92 | $17,940 | $12,396 | 69.1% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2022 | 41 | 355 | $53,250 | $5,222 | 9.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $6,600 | $2,927 | 44.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $6,300 | $2,696 | 42.8% |
About Charles Rose
Charles Rose is a Infectious Disease healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1568595874.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Charles Rose has received a total of $42,996 in payments from pharmaceutical and medical device companies, with $12,168 received in 2024. These payments were reported across 752 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($14,068).
As a Medicare-enrolled provider, Rose has provided services to 3,872 Medicare beneficiaries, totaling 317,373 services with total Medicare billing of $701,451. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Lexington, KY
- Active Since 03/14/2007
- Last Updated 03/04/2008
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1568595874
Products in Payments
- Fetroja (Drug) $11,572
- XERAVA (Drug) $9,553
- XACDURO (Drug) $5,229
- Arikayce (Drug) $977.30
- DOVATO (Drug) $945.82
- VIBATIV (Drug) $697.33
- NUZYRA (Drug) $646.76
- Cresemba (Drug) $543.65
- DIFICID (Drug) $464.20
- Vabomere (Drug) $351.40
- Veklury (Drug) $306.75
- ISENTRESS (Drug) $284.94
- AVYCAZ (Drug) $227.73
- PIFELTRO (Drug) $224.66
- Biktarvy (Drug) $209.80
- RUKOBIA (Drug) $203.17
- Rezzayo (Drug) $200.55
- VOWST (Biological) $176.87
- ZERBAXA (Drug) $167.98
- AMBISOME (Drug) $152.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Lexington
Dr. David Dougherty, M.d, M.D
Infectious Disease — Payments: $110,300
Infectious Disease $110,300
Daniel Rodrigue, Md, MD
Infectious Disease — Payments: $50,659
Infectious Disease $50,659
Dr. Marty Allen, M.d, M.D
Infectious Disease — Payments: $39,505
Infectious Disease $39,505
John Meek, Md, MD
Infectious Disease — Payments: $13,273
Infectious Disease $13,273
Mark Dougherty, Md, MD
Infectious Disease — Payments: $12,643
Infectious Disease $12,643
Dr. Andrea Banks, Md, MD
Infectious Disease — Payments: $9,877
Infectious Disease $9,877